Skip to main content
Banner background

Health Care Professional Resources

Safety, Dosing, and Administration Guide PDF

TABRECTA Safety, Dosing, and Administration Guide

This brochure highlights the TABRECTA® (capmatinib) tablets safety profile and offers guidance on dose modifications. An informational sheet for patients with important reminders about administration and side effects is also included.
Download
Patient Support Resources Brochure PDF

Patient Support Resources Brochure

Learn how Novartis can help support your patients with mNSCLC.
Download

Patient Resources

Patient Treatment Brochure PDF

Treatment With TABRECTA Patient Brochure

A comprehensive resource to prepare patients for their treatment journey with TABRECTA® (capmatinib) tablets.
Download

Important Safety Information

Interstitial Lung Disease (ILD)/Pneumonitis. ILD/pneumonitis, which can be fatal, occurred in patients treated with TABRECTA. ILD/pneumonitis occurred in 4.8% of patients treated with TABRECTA in the GEOMETRY mono-1 study, with 1.9% of...

Indication

TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION